Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31

Mirum Pharmaceuticals, Inc. (ISIN US60471A1034) closed at USD 98.22 on the Nasdaq on September 22, 2026, down 2.4 percent from the previous close. The latest market snapshot also places the company at a market capitalization of USD 6.38 billion and shows a consensus price target of USD 137.31.

Consensus target remains higher

According to MarketBeat on September 22, 2026, analysts tracked for Mirum Pharmaceuticals had a consensus price target of USD 137.31, implying 39.8 percent above the quoted share price of USD 98.22. The same snapshot assigns the stock a 1-year performance of 23.7 percent, creating a clear contrast between the positive annual return and the 2.4 percent decline recorded for the latest completed session.

The target figure is a market estimate rather than company guidance. Its relevance depends on the earnings path, commercial execution and the valuation investors are willing to assign to Mirum's medicines.

Revenue reaches USD 521.31 million

The September 22 market overview lists Mirum Pharmaceuticals revenue of USD 521.31 million, net income of negative USD 23.36 million and earnings per share of negative USD 14.55. Because the snapshot labels these values as company metrics without a visible quarterly or fiscal reporting period, they are presented here as quoted market data rather than as a newly reported interim result.

That combination gives the stock a specific tension. Revenue of USD 521.31 million provides a measurable commercial base, while net income of negative USD 23.36 million shows that revenue has not translated into positive earnings in the cited data. The gap between the USD 98.22 share price and the USD 137.31 consensus target is therefore tied to future earnings expectations, not to current profitability alone.

Nasdaq valuation sets the frame

Mirum's USD 6.38 billion market capitalization as of September 22, 2026 places the stock in a valuation-sensitive position. The cited data also show 433 employees, while the latest quoted share price is 2.4 percent below the preceding close and 23.7 percent above its level one year earlier.

For investors, the key measurable checkpoint is whether subsequent reported periods improve the relationship between revenue and net income. Until then, the current market picture combines a USD 98.22 Nasdaq price, negative quoted earnings of USD 14.55 per share and a consensus target of USD 137.31.

Mirum stock closes at USD 98.22

Mirum Pharmaceuticals stock closed at USD 98.22 on the Nasdaq on September 22, 2026, with a daily change of negative 2.4 percent. The market capitalization was USD 6.38 billion on the same date.

More news and analyses on Mirum Pharmaceuticals stock